logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • CD20-directed Cytolytic Antibody class drugs

    FiltersReset Filters
    8 results

    • briumvi

      (ublituximab)
      TG Therapeutics, Inc.
      Usage: BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • gazyva

      (obinutuzumab)
      Genentech, Inc.
      Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.

    • kesimpta

      (ofatumumab)
      Novartis Pharmaceuticals Corporation
      Usage: KESIMPTA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • ocrevus

      (ocrelizumab)
      Genentech, Inc.
      Usage: OCREVUS is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as primary progressive MS in adults.

    • ocrevus zunovo

      (ocrelizumab and hyaluronidase)
      Genentech, Inc.
      Usage: OCREVUS ZUNOVO is indicated for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as primary progressive MS, in adults.

    • rituxan

      (rituximab)
      Genentech, Inc.
      Usage: RITUXAN is indicated for the treatment of various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV) in adults and pediatric patients, as specified.

    • rituxan hycela

      (rituximab and hyaluronidase)
      Genentech, Inc.
      Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.

    • ruxience

      (rituximab-pvvr)
      Pfizer Laboratories Div Pfizer Inc
      Usage: RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.